Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Ajanta Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ajanta Pharma Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Ajanta Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ajanta Pharma (NSE:AJANTPHARM) has a Buyback Yield % of 0.00 as of Sep. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ajanta Pharma and its competitors. Over the past decade, Ajanta Pharma's Buyback Yield % has ranged from 0.01 to 1.85. According to the industry distribution chart, Ajanta Pharma ranks #999999 out of 234 companies in the Drug Manufacturers industry.
Is Ajanta Pharma's Buyback Yield % too high?
Ajanta Pharma's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.85. Based on the distribution chart, Ajanta Pharma ranks #999999 out of 234 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ajanta Pharma ranks #999999 out of 234 companies for Buyback Yield %. This places Ajanta Pharma in the lower half of its industry. Historically, Ajanta Pharma's own Buyback Yield % has ranged from 0.01 to 1.85 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ajanta Pharma and its competitors. Ajanta Pharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (NSE:AJANTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,481.70 — trading 4% above its estimated fair value. The current Buyback Yield % is 0.00. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Ajanta Pharma (NSE:AJANTPHARM), the current Buyback Yield % is 0.00 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ajanta Pharma (NSE:AJANTPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued.
The current stock price of ₹3,481.70 is trading 4% above its estimated GF Value™ of ₹3,348.50.
GuruFocus considers Ajanta Pharma to be Fairly Valued.
Key valuation signals for NSE:AJANTPHARM:
Buyback Yield %: 0.00
GF Value™: ₹3,348.50 vs. price of ₹3,481.70 (4% above fair value)
No single metric tells the full story. See the NSE:AJANTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score
Get the complete analysis for NSE:AJANTPHARM
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AJANTPHARM has been successfully added to your 
